LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Aandelen Lijst・Erasca Inc

Erasca Inc

Gesloten

11.11 7.97

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

10.37

Max

11.43

Belangrijke statistieken
By Trading Economics
Inkomsten	-154M -183M
EPS	-0.6
Werknemers	103
EBITDA	-5.3M -37M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+96.41% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-53M 3.2B
Vorige openingsprijs	3.14
Vorige sluitingsprijs	11.11

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

1.39 / 1.44 Steun & Weerstand

Erasca Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mei 2026, 22:02 UTC

Winsten

ZTO Express (Cayman): Di Xu to Resign From Board

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mei 2026, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mei 2026, 21:37 UTC

Winsten

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mei 2026, 21:01 UTC

Winsten

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mei 2026, 20:58 UTC

Winsten

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mei 2026, 20:46 UTC

Populaire aandelen

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mei 2026, 20:43 UTC

Marktinformatie

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mei 2026, 20:34 UTC

Winsten

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q EPS 5c >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q Sales $1.4B >JHX

19 mei 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mei 2026, 20:18 UTC

Marktinformatie

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mei 2026, 19:23 UTC

Marktinformatie

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Vergelijking

Prijswijziging

Erasca Inc Prognose

Koersdoel

By TipRanks

96.41% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20.27 USD 96.41%

Hoogste 30 USD

Laagste 9 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Erasca Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Erasca Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.39 / 1.44Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.